The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
